On Nov. 18, 2026, Recursion shares climbed after regulators aligned on its lead familial adenomatous polyposis trial, though ...
This pharmaceutical-development technology company continues to demonstrate that its testing platform has real potential.
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results